Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...

Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform

Management raised full-year guidance on strong hip and technology segment growth.

Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constan

Zimmer Biomet Holdings (ZBH) just paired stronger than expected quarterly results with a guidance increase, as management pointed to solid execution in U.S. hip and technology lines and progress in its sales force restructuring. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet Holdings' recent guidance lift and Q2 beat come after a period of mixed returns, with the share price at US$97.19 and a 90-day share price return of 18.05%. However, the 5-year total shareholder return...

Zimmer Biomet Holdings is back in focus as analysts fine tune their price targets around recent research and earnings news. Targets such as US$110, US$95 and US$93 reflect a mix of supportive and cautious views on how the current share price lines up with execution and growth expectations. As you read on, you will see how these moves fit into the evolving narrative and what to watch next to stay on top of sentiment around Zimmer Biomet Holdings. Stay updated as the Fair Value for Zimmer...

The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.

Zimmer Biomet Holdings Inc (ZBH) raises full-year outlook on robust US hip and technology growth, while navigating ongoing commercial transformation and international headwinds.

Moby summary of Zimmer Biomet Holdings, Inc.'s Q2 2026 earnings call